Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Michael Parini sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction on Monday, July 13th. The stock was sold at an average price of $292.05, for a total value of $620,606.25. Following the sale, the executive vice president now owns 28,963 shares in the company, valued at $8,458,644.15. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Michael Parini also recently made the following trade(s):
- On Wednesday, April 29th, Michael Parini sold 2,125 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $254.95, for a total value of $541,768.75.
Shares of VRTX stock opened at $293.83 on Thursday. Vertex Pharmaceuticals Incorporated has a 52-week low of $165.23 and a 52-week high of $306.08. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.42 and a current ratio of 3.54. The firm has a market capitalization of $76.18 billion, a P/E ratio of 52.38, a P/E/G ratio of 1.41 and a beta of 0.94. The stock has a 50 day moving average price of $283.38 and a 200 day moving average price of $252.28.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, April 29th. The pharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.84 by $0.72. The business had revenue of $1.52 billion during the quarter, compared to analyst estimates of $1.28 billion. Vertex Pharmaceuticals had a return on equity of 25.69% and a net margin of 31.35%. Vertex Pharmaceuticals’s revenue was up 76.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 EPS. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 7.35 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Capital International Investors grew its stake in Vertex Pharmaceuticals by 107.2% during the 4th quarter. Capital International Investors now owns 6,264,794 shares of the pharmaceutical company’s stock valued at $1,371,677,000 after purchasing an additional 3,241,404 shares during the last quarter. Norges Bank purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth about $551,229,000. Capital World Investors boosted its stake in shares of Vertex Pharmaceuticals by 18.7% in the first quarter. Capital World Investors now owns 12,579,718 shares of the pharmaceutical company’s stock worth $2,993,340,000 after buying an additional 1,981,607 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Vertex Pharmaceuticals by 5.7% in the first quarter. BlackRock Inc. now owns 22,326,048 shares of the pharmaceutical company’s stock worth $5,312,483,000 after buying an additional 1,209,227 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Vertex Pharmaceuticals by 22.1% in the first quarter. Jennison Associates LLC now owns 4,361,755 shares of the pharmaceutical company’s stock worth $1,037,880,000 after buying an additional 790,506 shares during the last quarter. 93.42% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on the company. Piper Sandler reaffirmed a “buy” rating and issued a $300.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, April 27th. BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Morgan Stanley downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $277.00 to $300.00 in a research report on Wednesday, July 8th. They noted that the move was a valuation call. Oppenheimer upped their target price on Vertex Pharmaceuticals from $265.00 to $305.00 and gave the company an “outperform” rating in a report on Thursday, April 30th. Finally, Citigroup upped their target price on Vertex Pharmaceuticals from $305.00 to $325.00 and gave the company a “buy” rating in a report on Friday, June 12th. Ten equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $289.73.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Featured Article: Diversification in Investing
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.